ArticleBriefings in functional genomics2025
Dual oncogenic roles of TPD52 and TPD52L2 in gastric cancer progression via PI3K/AKT activation and immunosuppressive microenvironment remodeling.
Article in Briefings in functional genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging roles and therapeutic potential of non-coding RNA in osteosarcoma: a review.Medical oncology (Northwood, London, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
aimTPD52 (tumor protein D52) and TPD52L2 (tumor protein D52-like 2), members of the TPD52 gene family, have been implicated in multiple malignancies. However, their roles in gastric cancer (GC) remain elusive. Herein, we integrated multiomics analyses and experimental validation to elucidate their prognostic and functional significance in GC.
methodsUtilizing The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and tissue microarray datasets, we analyzed TPD52/TPD52L2 expression patterns in patients with GC. Survival analysis, Cox regression, and nomogram construction were performed to assess prognostic value. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes functional enrichment analysis and immune infiltration evaluation (Cell-type Identification By Estimating Relative Subsets Of RNA Transcripts/Estimation of STromal and Immune cells in MAlignant Tumour tissues using Expression data) (CIBERSORTx/ESTIMATE) were conducted to explore the molecular mechanisms involved. In vitro experiments (cell proliferation, migration, invasion, and apoptosis assays) were performed via lentivirus-mediated gene knockdown in gastric cancer cell lines AGS and MKN45 cells.
resultsTPD52 and TPD52L2 were significantly overexpressed in GC tissues compared with their normal counterparts. Elevated TPD52L2 expression was significantly associated with advanced Tumor, Node, Metastasis (TNM) stage and independently predicted reduced overall survival according to multivariate Cox regression. Multivariate analysis identified TPD52L2 as an independent prognostic factor. Diagnostic Receiver Operating Characteristic (ROC) curves yielded area under the curve values of 0.813 (TPD52) and 0.807 (TPD52L2). The results of functional experiments suggested that TPD52/TPD52L2 knockdown inhibited proliferation, migration, G0/G1 arrest, and induced apoptosis. Mechanistically, TPD52/TPD52L2 silencing suppressed PI3K/Akt serine/threonine kinase (AKT)/mammalian target of rapamycin (mTOR) signaling and epithelial-mesenchymal transition marker expression.
conclusionTPD52 and TPD52L2 are promising prognostic biomarkers in GC, with TPD52L2 exhibiting greater clinical relevance. Targeting these proteins may disrupt oncogenic signaling pathways and enhance immunotherapy efficacy, warranting further investigation in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.